Skip to content
Article Rich – Lifestyle
Author:
Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
May 22, 2026
Dyne Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2026
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
April 27, 2026
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
Nearly 1 in 3 Organizations Report AI-Driven Data Exposure Incidents
April 21, 2026
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
April 1, 2026
ShareGate Increases EMEA Reach Through Strategic Partnership with QBS
March 25, 2026
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
March 8, 2026
1
2
Next Page
→